Definium Therapeutics Stock (DFTX) Soars on a Public Offering Pricing After Strong Trial Results
I'm LongbridgeAI, I can summarize articles.Definium Therapeutics (DFTX) stock surged following the pricing of a $700 million public offering at $34 per share. The funds will support R&D for DT120, its lead drug for major depressive disorder, and potential commercialization if FDA-approved. This financing follows strong Phase 3 trial results, driving a 22.37% daily gain and significant year-to-date growth. Wall Street analysts maintain a 'Strong Buy' consensus with an average price target of $56.73.
Definium Therapeutics (DFTX) stock soared on Wednesday after the clinical-stage biopharmaceutical company announced a public offering. The company is set to raise $700 million from a public offering of DFTX stock. This offering includes 20.6 million shares of the company's stock that were priced at $34 each. There's also a 30-day option for underwriters to acquire an additional 3.1 million shares. Several large firms, including J.P. Morgan (JPM), Jefferies (JEF), Leerink Partners, and BofA Securities (BAC), have backed the offering.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to Definium Therapeutics, the funds raised from this offering will be used for research and development of its product candidates. It also intends to use the funds for the commercialization of DT120 ODT if it is approved by the U.S. Food and Drug Administration (FDA). Other uses of the funds include working capital and general corporate purposes.
The funding comes just days after Definium reported strong Phase 3 results for DT120, its lead drug for major depressive disorder. That clinical trial success also spurred increased interest in DFTX stock from both analysts and investors. As a result, the shares have gained 78.98% over the past five days of trading.
Definium Therapeutics Stock Movement Today
Definium Therapeutics stock was up 22.37% on Wednesday, extending a 230.43% year-to-date rally. Investors will also note that the stock has soared 428.95% over the past 12 months.
DFTX stock trading activity was above average today, as some 6.72 million shares changed hands. For comparison, the company's three-month average daily trading volume is about 1.97 million shares.
Is Definium Therapeutics Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts' consensus rating for Definium Therapeutics is Strong Buy, based on 12 Buy ratings over the past three months. This comes with an average DFTX stock price target of $56.73, suggesting a potential 28.2% upside for the shares.